Back to top
more

Collegium Pharmaceutical (COLL)

(Delayed Data from NSDQ)

$36.71 USD

36.71
643,177

+1.09 (3.06%)

Updated Aug 13, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Will Cronos Group (CRON) Report Negative Earnings Next Week? What You Should Know

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

COLL or ZTS: Which Is the Better Value Stock Right Now?

COLL vs. ZTS: Which Stock Is the Better Value Option?

MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Benjamin Rains headshot

Find 'Strong Buy' Stocks Near their Highs for February

Let's explore a Zacks screen that helps investors find 'Strong Buy' stocks trading near their highs as we head into February...

Zacks.com featured highlights MercadoLibre, Axcelis Technologies, Shinhan Financial, Pinduoduo and Collegium Pharmaceutical

MercadoLibre, Axcelis Technologies, Shinhan Financial, Pinduoduo and Collegium Pharmaceutical have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength Amid January Rally

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are MELI, ACLS, SHG, PDD and COLL.

Rimmi Singhi headshot

Lift Portfolio Value With These 5 High Earnings Yield Picks

RGA, JBL, LBRT, CGAU and COLL are a few high earnings yield value stocks that could be good additions to your portfolio now.

Relay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock?

Relay Therapeutics, Inc. (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

COLL vs. ZTS: Which Stock Is the Better Value Option?

COLL vs. ZTS: Which Stock Is the Better Value Option?

Collegium Pharmaceutical (COLL) Lags Q3 Earnings Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -9.84% and 2.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Collegium Pharmaceutical (COLL) Q2 Earnings Miss Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -90.08% and 0.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of -26.67% and 12.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?

Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.

Collegium Pharmaceutical (COLL) Lags Q1 Earnings Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids

A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.

Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag

The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.

INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate

INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.

Actinium (ATNM) Up on Commercialization Deal With Immedica

Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.

Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines

Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.

FDA Finds Deficiencies in Myovant (MYOV), Pfizer's Myfembree sNDA

Though the FDA identified deficiencies in Myovant's (MYOV) Myfembree sNDA for managing endometriosis-associated pain, a final decision on the application is yet to be communicated.